The Pathway to a Better Tomorrow: Big Data and Innovation

The Pathway to a Better Tomorrow: Big Data and Innovation

Big Data illustration

We continue our journey into the world of R&D and Big Data with the last chapters of our filmed interview, in which two Healthcare and Life Science industry leaders, Dr. Pierre Meulien and Dr. Dipak Kalra, discuss the future of these industries, and the ways in which Big Data and R&D will change the health world – and our lives.

Interviewed by Dr. Philippe Salphati, Managing Director and Partner at Tefen


List of Videos:

1. Meet our experts (previous part)
2. The history of Big Data (previous part)
3. Big Data - Big change (previous part)
4. What is the key competitive advantage? (below)
5. Big Data collaboration = innovation (below)


In the previous Tefen Tribune issue (and the one before) we shared a special filmed interview, featuring Dr. Pierre Meulien and Dr. Dipak Kalra, who discussed the history of Big Data analytics, Artificial Intelligence in R&D (life sciences) and healthcare, and the current challenges these fields are facing.

In this Tribune issue, we close with the final two parts of this special filmed interview, in which these two industry leaders discuss the future of these major fields, especially the Big Data Revolution.

How will the Big Data revolution impact Life Science and Healthcare organizations? What will be the different ways and tools by which these industries handle the future of data collection, the collaboration between the two industries, and the use of data when managing personal health?

And speaking of the future, how will life look like in 2050, considering the issues and questions that these progressing fields will bring and raise – how will these issues affect our health and our lives?

4. What is the key competitive advantage? (16:24) 

Here are selected quotes from this issue's video interviews. We welcome you to watch the full interviews and dive into the exciting future that the innovative Big Data world holds:

The Future of Big Data 

5. Big Data collaboration = innovation (7:29) 

Will the ability to leverage Big Data have significant impact on innovation in the future, both in terms of the healthcare system but also in R&D and Life Science organizations?

Pierre Meulien: It'll be absolutely essential for companies to leverage Big Data. If they do not – they will die. The ways these companies will do it will be the key. Whether they do it alone in a competitive way, or they do it together in a pre-competitive way.

Dipak Kalra: From the healthcare perspective, there are couple of big challenges: privacy protection, especially when one deals with personal data that then goes to an anonymized place for research use; and the fact that there still is quite a lot to do to improve the interoperability between hospitals, GPs, research systems, registries – so that the data can really come together and be analyzed at scale. These are two big challenges. 

But another challenge, is that the race is not competitively to gain the insights and facts from the data. The race competitively is to turn an insight into new organizational practices, inside a competitive industry like pharma.

In a non-competitive place, usually healthcare organizations like hospitals want to use Big Data research to improve their care.

The successful hospitals won't be the ones who discover the facts from the data, but the ones who turn the data into improved organizational processes, improved clinical care, improved patient experiences. The big challenge is using the knowledge and insights to make a difference to how you behave.

How would the world of science, healthcare, innovation, and R&D, look like in 2050?

Innovation - a hand on an innovative screen

Pierre Meulien: Arthur Kornberg, a very famous scientist who won the Nobel Prize for the discovery for DNA polymers, had a famous quote which said, "the future is invented – not predicted."

The development of technology, the speed at which this is going is very challenging to understand what's going to happen, and the industry ecosystem will be totally changed in 2050.

We'll have players who will be much more joined-up, and if the pharmaceutical companies cannot partner effectively with the IT people and small or mid-sized biotech companies, they would die. They would need to continually renew themselves and their business models and build those required partnership.

We have no clue how fast the technology will develop – all we know is that it will. And our abilities to monitor our own health through remote devices etc., that we're already seeing, will be incredible.

We would be measuring biomotions of data points in our bodies. This data will be going somewhere to be analyzed, and we'll be in constant contact with those providers of this service, that will hopefully keep us healthy as long as possible.

Dipak Kalra: People would become their own primary health care providers. They will be interacting in a two-way relationship with sensors, apps, and other things, that give a personal guidance system for managing and optimizing personal health. They will need to cross-fertilize self-management, because diseases interact.

We will also have connectivity with a large data pool of patients, very closely profiled to each of us, possibly at a global level by 2050. We will engage first and foremost with Smart apps that guide each of us and tell us what to do on routine fine measures.

The second wave of connectivity might be to a community of people in that database, who have similar condition to each of us, and we may then share, if you like, folk knowledge informed by evidence that we are given in a "just-in-time" way.

We may have moved from a one-to-one or one-to-many patient-healthcare professional relationship, to a more many-to-many relationship, that is, rather than a person seeing a clinician – he may consult his network. If we can't resolve an issue, we consult collectively with a panel of virtual and physical actors, who help us with their expert knowledge.

But of course, a person still needs to see health professionals, who will no doubt have incredibly smart ICT tools, as well as virtualization tools and non-invasive tools to diagnose him.

And so, with prior consent, everything collected about each of us will be going into the real-time learning pool. So the evidence generation is close to real-time.

Dr. Philippe Salphati

Managing Director and Partner at Tefen Europe

Digital Transformation, Business Design and Transformation, and Commercial Excellence expert in the Life Sciences sector

Talk to Dr. Philippe Salphati

Fill the form for some quick advice


Let's work together!

shijiebei 365bet manbetx 188bet xinshui caipiao 95zz tongbaoyule beplay 88bifa 18luck betway bwin hg0088 aomenjinshayulecheng ca88 shenbotaiyangcheng vwin w88 weide